Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies how well giving azacitidine together with etanercept works in
treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as
azacitidine, works in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may
protect normal cells from the side effects of chemotherapy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium